Cogent Positive Updated Lead-In Data from Ongoing Phase 3 GI Cancer Trial

 

• Bezuclastinib + sunitinib combination therapy reached median progression free survival (mPFS) of 19.4-months and 33% ORR in subset of advanced GIST patients with one prior treatment

• Encouraging long-term safety and tolerability with combination bezuclastinib and sunitinib therapy in Part 1
  

• PEAK Phase 3 guidance accelerated with enrollment completion now expected in 3Q 2024
  

• Company announces new advanced GIST clinical trial sponsored by the Sarcoma Alliance for Research through Collaboration (SARC) and in collaboration with The Life Raft Group and Dana-Farber Cancer Institute

https://www.globenewswire.com/news-release/2024/05/23/2887694/0/en/Cogent-Biosciences-Announces-Positive-Updated-Lead-In-Data-from-Ongoing-Phase-3-PEAK-Trial-Evaluating-Bezuclastinib-in-Combination-with-Sunitinib-in-Patients-with-Gastrointestinal-.html